Molina J-M, et al. Doravirine (DOR) versus ritonavir-boosted darunavir (DRV+r): 96-week results of the randomized, double-blind, phase 3 DRIVE-FORWARD Noninferiority trial. AIDS 2018.
WHO introduceert de ‘Toolkit for research and development of paediatric antiretroviral drugs and formulations’
sep 2019 | HIV